12/29/2008

Johnson & Johnson has completed a $438 million tender offer for Omrix Biopharmaceuticals. J&J obtained nearly 98% of Omrix's shares and said it intends to finalize the buyout as soon as possible. Omrix is expected to operate as an independent business under Ethicon, a J&J subsidiary.

Related Summaries